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presence of reentry, we decided to add left AX-P because
the bilateral axillary arteries had been routinely prepared
for selective cerebral perfusion at the Hiroshima University
Hospital. The addition of FA-P might be another strategy in
other institutions.
Because there are unpredictable factors in acute aortic dis-
section, decisions need to be made stepwise and be based on
real-time information at each step. Although our initial as-
sessment was incorrect, TEE and orbital Doppler findings
steered the subsequent management toward a good outcome.
Compression of IA can be a mechanism of malperfusion
after right AX-P. In acute aortic dissection with many unpre-
dictable factors, real-time, on-site information is essential for
intraoperative navigation.
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FIGURE 2. Intraoperative transesophageal echocardiogram demonstrating the narrow true lumen of the IA.
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Leuven, Belgium, College Park, Md, Louisville, Ky, Newark, NJ and New York, NYThe clinical benefits of implantable left ventricular assist de-
vices (LVADs) as a bridge to transplant and for destination
therapy have been demonstrated.1-3 The low rate of LVAD
use is attributed to the invasive nature of the implantation
surgery and the relatively high rate of complications.4 If
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states, the flow requirements could be reduced.
The Synergy Micro-Pump (CircuLite, Inc, Hackensack NJ)
is approximately the size of a size AA battery, weighs only
25 g, and can pump as much as 2.5 to 3 L/min. Its small size
permits insertion through a right-sided minithoracotomy.
The pump is then placed subcutaneously in the pectoral re-
gion, similar to a pacemaker. This is the first clinical report
describing the Synergy Micro-Pump’s implantation proce-
dure, hemodynamic effects, and clinical results.
CLINICAL SUMMARY
The patient was a 46-year-old man (weight 85 kg, height
184 cm, body surface area 2.01 m2) without significant illness
in his medical history who had a large anterior myocardial in-
farction in March 2007. New York Heart Associationardiovascular Surgery c Volume 137, Number 1 243
Brief CommunicationsFIGURE 1. Drawing illustrating pump position and direction of pump flow with radiographic correlation in anteroposterior view. A. & V. subclavia dext.,
Right subclavian artery (red) and vein (purple).functional class IV symptoms developed within 2months (car-
diac index 2.2 L/[min/m2], pulmonary arterial pressure 55/24
mmHg, pulmonary capillary wedge pressure 31mmHg,max-
imum oxygen consumption 8.5 mL kg/min). The patient was
listed for a heart transplant. His condition continued to deteri-
orate during the ensuing 6 weeks, however, and he was ac-
cepted for investigational study of the Synergy Micro-Pump.
This study was conducted in accordance with the Declaration
of Helsinki according to a study protocol approved by the
Leuven University Ethics Committee and the Belgian Compe-244 The Journal of Thoracic and Cardiovascular Sutent Authority. The study protocol was approved by the Uni-
versity Hospitals Leuven Ethical Committee on April 10,
2007.
After informed consent was obtained (June 28, 2007), the
patient underwent elective surgery. Hemodynamics after an-
esthesia included an arterial pressure of 96/69 mm Hg, a car-
diac output of 2.5 L/min, a pulmonary arterial pressure of 55/
24 mm Hg, and a pulmonary capillary wedge pressure of 31
mm Hg. A 4-cm subclavicular incision was made to isolate
the right subclavian artery. A small subcutaneous pocket,TABLE 1. Clinical indices of heart failure and device function
Preoperative POD 3 POD 30 POD 70 POD 100
Body weight (kg) 83 85 88 85 88
Heart rate (beats/min) 96 94 92 85 78
New York Heart Association class IV IV III II II
Arterial blood pressure (mm Hg) 85/65 94/69 97/70 92/64 11/78
Cardiac index (L/[min $ m2]) 1.38 2.7 1.7 2.0 2.38
NT pro-BNP (ng/L) 4698 — 4020 3129 2754
Renal function
Serum sodium (mmol/L) 131 135 137 135 133
Serum creatinine (mg/dL) 1.15 0.68 1.19 1.06 1.27
Blood urea nitrogen (mg/dL) 56 22 47 44 66
Plasma free hemoglobin* (mg/dL) <5 7 <5 <5 <5
Pump speed (rpm) — 22,000 20,000 22,000 22,000
Estimated pump flow (L/min) — 2.5 2 2.5 2.5
Medication
Bumetanide (mg) 2.5 bid — — 1 bid 2.5 bid
Furosemide (mg) — 40 qd 40 qd — —
Perindopril (mg) 2 bid 2 bid 2 bid 4 bid 4 bid
Carvedilol (mg) 3.125 qd 3.125 bid 3.125 bid 6.25 bid 6.25 bid
POD, Postoperative day; NT pro-BNP, N-terminal pronormone brain natriuretic peptide; bid, twice daily; qd, daily. *As index of hemolysis.rgery c January 2009
Brief Communicationssimilar to a pacemaker pocket, was formed for the pump an-
terior to the right pectoralis major muscle. An incision was
then made in the right fourth intercostal space to gain access
to the left atrium through the Waterson groove. The nitinol-
reinforced silicone inflow cannula was inserted into the left
atrium between the insertions of the right upper and lower
pulmonary veins. The inflow cannula was tunneled through
the second intercostal space to exit the thorax in the area of
the subcutaneous pocket. The 8-mm expanded polytetra-
fluoroethylene outflow graft was anastomosed to the subcla-
vian artery. The electrical wire of the pump was then
tunneled to exit the body over the right lower quadrant of
the abdomen. Pump speed was set at 22,000 rpm (pump
flow approximately 2.5 L/min), the surgical wounds were
closed, and the patient was taken to the intensive care unit.
The duration of the surgery was approximately 2 hours.
Pump position is illustrated in Figure 1.
The patient recovered well from the surgery. Daily therapy
was started with warfarin sodium (target international normal-
ized ratio 2.5) and low-dose aspirin (80mg). The patient is cur-
rently ambulatory. He continues to improve his exercise
capacity at home,makes visits, and climbs stairs. Table 1 sum-
marizes the evolution of clinical parameters during the first 100
days after the procedure.
The patient had only minor complications. A hematoma
developed at the subclavicular wound site on postoperative
day 1 but had resolved by postoperative day 4. Transient
swelling developed in the right upper extremity on postoper-
ative 4 but had resolved by postoperative day 7.
DISCUSSION
We summarize here the first use of the Synergy Micro-
Pump in a patient as a bridge to transplant. This device pro-A bilobed thoracic outlet mass: Opti
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The Journal of Thoracic and Cvides partial left ventricular support (2-3 L/min) and is spe-
cifically designed to be implanted in patients who are not as
critically ill as the patients now typically receiving full sup-
port LVADs. Because of the small size of the device, the sur-
gery was relatively short and significantly less traumatic
than with other LVADs. The combination of the patient’s in-
trinsic cardiac output of 3.6 L/min with the 2.5 L/min pro-
vided by the pump summed to a total cardiac output in
excess of 6 L/min, a normal resting value. No significant
hemolysis was noted, and there were no serious adverse
effects.
There are several unique features of the device. This pump
is the smallest implanted assist device ever used as a bridge
to transplant. This is the first implanted device with the in-
flow cannula placed in the left atrium and the outflow can-
nula connected to the subclavian artery. Because of the
unique anatomic position, the procedure was anticipated to
be less invasive. As a result, flows of only 2.5 L/min were
able to produce clinically significant and sufficient acute
hemodynamic effects.
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vascular structures. We present a hemiclamshell approach
with removal of the first rib to facilitate resection of a bilobed
mass compressing the right subclavian artery and brachial
plexus.
CLINICAL SUMMARY
A 31-year-old African-American man presented with a 1-
year history of increasing shoulder pain and right forearm
paresthesias. He denied any upper limb weakness, weight
loss, fever, or dyspnea. Clinical examination revealed
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